

Original Research article

***Terminalia chebula* mediated silver nanoparticles and its antibacterial activity against oral pathogens.**

Running Title: Antimicrobial Activity of Silver Nanoparticles Synthesized using *Terminalia chebula* against *Streptococcus mutans*, *Staphylococcus aureus* and *Enterococcus faecalis*.

Abstract

Background: Dental infections cause chronic disorders such as gingivitis, periodontitis, and dental caries when left untreated, resulting in irreversible tooth loss. However, solid preventive methods, such as employing promising herbs with well-documented health advantages like *Terminalia chebula*, can help to reduce the excessive expansion of dangerous oral flora like *Streptococcus mutans*, *Staphylococcus aureus*, and *Enterococcus faecalis*.

Aim: The goal of this study is to see how effective silver nanoparticles made from *Terminalia chebula* are against oral pathogens including *Streptococcus mutans*, *Staphylococcus aureus*, and *Enterococcus faecalis* at various doses.

Materials and Methodology: The plant extract was made from *Terminalia chebula*, followed by the synthesis of silver nanoparticles. The antibacterial efficacy of Ag-NPs in varied concentrations, namely 25, 50, and 100 L, was determined using the agar-well diffusion method, with amoxicillin acting as a positive control. For each plate, the zone of inhibition was recorded, and the findings were statistically analysed using one way anova and post hoc analysis using IBM SPSS software (Version 20.0)

Results: Following the synthesis of Ag-NPs, a colour shift was noticed. UV-vis spectroscopy was used to characterise the synthesized particles, which revealed a peak at 440nm. With a rise

in Ag-NP concentration, the antibacterial activity indicated an increase in zone of inhibition. The zone of inhibition for *S. aureus* was substantially higher than Amoxicillin at all doses of Ag-NPs ($p < 0.05$), whereas it was significantly lower for *E. faecalis* ($p < 0.05$). The zone of inhibition for *S. mutans* was substantially lower than amoxicillin at 25 μ L concentration ($p < 0.05$), but there was no significant difference at higher concentrations ($p > 0.05$).

Conclusion: Antibacterial activity of Ag-NPs derived from *Terminalia chebula* against dental pathogens, particularly *Staphylococcus aureus* and *Streptococcus mutans*, *Enterococcus faecalis*.

Keywords: Silver Nanoparticles, *Terminalia chebula*, Green synthesis.

1. Introduction

Nanotechnology is currently an enthusiastically growing field in the epoch of modern science. The size-dependent characteristics of nanoparticles give it its multi-dimensional nature that has been efficiently employed in the past in fields such as agriculture (1), physics, optics, medicine and electronics as catalysts, imaging probes, delivery systems, energy sources, scavengers, biological labels, diagnostic biosensors and as automotive parts (2) among several others. It has also been acknowledged that nanomaterials divulge new mechanical and chemical properties to everyday products, thus exponentially multiplying their functionality and longevity (3,4).

It is a well-documented fact that silver has a relatively low toxicity and a high biocompatibility when compared to most metals, thus greatly increasing its potential to be used in the pharmaceutical and healthcare industry (5). One amongst its many beneficial properties is its antimicrobial efficacy. Interestingly, it was found that bacteria killed by silver showed significant antibacterial potential against a viable population of the same bacterium. This is because the killed bacterium acts as a reservoir for silver and promotes further bactericidal activity - earning for itself a rather amusing term - the “Zombie’s Effect”. Thus, it exhibits a desirably long lasting and persistent bactericidal effect (6). This subsequently prevents bacterial re-colonisation and

proliferation. With the intention of harnessing the health benefits of silver, its nanoparticles were synthesized using metallic silver nitrate. Herbal formulations are being used in many systemic and oral diseases due to its therapeutic benefits with less side effects.(7–9)This was mediated by an herbal formulation of *T. chebula*. Although silver nanoparticles can be conventionally synthesised by availing physical and chemical methods, biosynthesis proves to be a better choice as it does not involve the use of hazardous chemicals (10) and it is economical, simple, high yielding, rapid and non-toxic. Biologically synthesised silver nanoparticles also exhibit exalted levels of stability and solubility (11).

Terminalia chebula is a native, cheap and commonly found plant with established health benefits. It has an extensive history of importance in Ayurveda (12) due to its use in kidney and liver dysfunctions, antitussive, cardiogenic, homeostatic, diuretic and laxative functions (13)(14). Thus, by using silver nanoparticles, we have aimed to exploit the merits of *Terminalia chebula*.

Streptococcus mutans is a gram-positive bacterium which is commonly found in the oral cavity and it plays an essential role in the pathogenesis of dental decay (15). It is one of the most vital initial colonizers of tooth surfaces that seeks to change its immediate local environment in terms of pH, coaggregation and substrate availability among several other factors – thereby allowing for more fastidious organisms to colonize and aggregate even further (16)(17)(18), finally resulting in the formation of dental plaque and calculus. This is because it is one of the few bacteria furnished with uncommon specialised receptors that enhance adhesion to tooth surfaces. It employs the use of the enzyme glucanase which converts sucrose into a sticky dextran-based polysaccharide that helps other organisms to cohere. As it metabolises dietary sucrose to lactic acid, an acidic environment with a low pH is created in the mouth which leads to the demineralisation of enamel – causing an increase in the vulnerability of teeth to dental decay (19). Other bacteria such as *Staphylococcus aureus*, *Streptococcus mitis*, *Streptococcus sanguinis* and *Enterococcus faecalis* have also been implicated in the development of dental caries, endodontic infections, peri-implantitis and gingival diseases (20)(21).

It was estimated that approximately 2.3 billion adults had dental caries in their permanent teeth and that more than 530 million children had decayed primary teeth in 2015 and its incidence only continues to increase despite having worldwide access to dental care (22). Also, with our current

scientific footing we cannot regenerate natural tooth structure once it has been lost (23). Thus, it is important to devise effective and inexpensive measures against dental distress causing pathogens such as *Streptococcus mutans*, *Staphylococcus aureus* and *Enterococcus faecalis* – subsequently giving this study its aim.

Our team has extensive knowledge and research experience that has translated into high quality publications (24–36),(37–41)(42)(43). Here, we have attempted to synthesize silver nanoparticles using an herbal formulation prepared from the fruits of *Terminalia chebula* and studied its antibacterial activity in different concentrations in comparison with the standard antibiotic amoxicillin.

2. Materials and Methodology

2.1 Preparation of the Plant Extract

Fruits of *Terminalia chebula* were freshly collected from Chennai in the month of January, 2021 and were thoroughly washed 3-4 times in double distilled water. They were then shade-dried for 7-14 days and were powdered using a mortar and pestle and stored in an airtight utensil. Later, 1 g of the powder was dissolved in distilled water and was boiled for 5-10 minutes at 60-70°C . The resulting solution was filtered using a Whatman No. 1 filter paper. Finally, the filtered plant extract was collected and stored at 4°C for further use.

2.2 Synthesis of Silver Nanoparticles

To make a metallic solution, 1 mM silver nitrate was dissolved in 90 ml double distilled water. To this, 10 mL of *Terminalia chebula* fruit extract was added, resulting in a 100 mL formulation. Its colour change was very appealing, and photographs were taken to capture it methodically. For the creation of its nanoparticles, the formulation was held in a magnetic stirrer at 700 rpm for 48 hours.

2.3 Characterisation of the Synthesised Silver Nanoparticles

The synthesis of silver nanoparticles was initially characterised by using UV-vis-spectroscopy, where 3 ml of the solution was taken in a cuvette and scanned in a UV-vis-spectrometer within a wavelength field limit of 250 nm to 750 nm. The results were recorded for its graphical analysis.

2.4 Preparation of the Silver Nanoparticle Powder

The silver nanoparticle formulation was centrifuged in a Lark refrigerated centrifuge. The centrifugation was done at 8000 rpm for a time duration of 10 minutes and the resultant pellet was collected and then washed twice with distilled water. It was later purified and dried at 60°C using a hot air oven. Finally, the silver nanoparticle powder obtained was collected and stored in an air-tight Eppendorf tube.

2.5 Study of Anti-bacterial Activity of Ag-NPs Against *Streptococcus mutans*, *Staphylococcus aureus* and *Enterococcus faecalis*

The Agar-Well Diffusion Method was used to assess the antimicrobial efficacy of Ag-NPs. Different dilutions of Ag-NPs were tested against 3 organisms - *Streptococcus mutans*, *Staphylococcus aureus* and *Enterococcus faecalis*. The fresh bacterial suspensions were dispersed on the surface of Muller-Hinton Agar containing plates. Ag-NP concentrations of (25, 50 & 100µL) were incorporated into the wells and the plates were then incubated at 37°C for 24 hours. Antibiotics were used as a positive control and the zone of inhibition were recorded for each well.

2.6 Statistical Analysis

The data was recorded in a Microsoft Excel 2016 (Microsoft Office 10) spreadsheet and was later exported to the Statistical Package for the Social Sciences for Windows (Version 20.0, SPSS, Inc., Chicago, USA) where it was subjected to statistical analysis. A one-way ANOVA test was used with the level of significance set at $p < 0.05$ followed by a Post Hoc (Tukey HSD) test with the confidence interval set at 95%.

3. Results and Discussion

3.1 Visual Observation

A colour change was visually observable after the synthesis of nanoparticles. The extract had turned a dark brown from its initial white colour. This colour change from white to dark brown caused by the excitation of surface plasmon resonance primarily confirms the formation of Ag-NPs.




Figure 1 – Colour change image of *T. chebula* mediated silver nanoparticles.

3.2 UV-vis-Spectroscopy

The bioreduction of pure silver nitrate to silver nanoparticles was characterised by employing UV-vis-spectroscopy. This was carried out to assess the successful formation and stability of the Ag-NPs. It was done using a UV-vis-spectrometer within a wavelength field limit of (250 – 750nm). The Surface Plasmon Resonance peak was noted at 440 nm. This is in line with the comparable findings of 437 nm, 400 nm - 440 nm and 450 nm in similar studies conducted by

Vidhya *et al.* in 2021 (44), Chandra Sekhar *et al.* in 2016 (45) and Prathibha *et al.* in 2015 (46) respectively.




Figure 2 - UV visible spectra of biosynthesized silver nanoparticles

3.3 Antibacterial Activity

The antimicrobial activity for three different concentrations of our silver nanoparticle solution were measured and recorded in 3 plates containing unique microbes - *Streptococcus mutans*, *Staphylococcus aureus* and *Enterococcus faecalis* - simultaneously being scaled against the antibiotic drug control in use. All measurements were done in triplicate.




Figure 3 - Showcasing the effect of various concentrations of Ag-NPs on *Streptococcus mutans* with their zones of inhibition:

1. Effect of 25 μL of Ag-NPs on *Streptococcus mutans* with its moderately sized zone of inhibition
2. Effect of 50 μL of Ag-NPs on *Streptococcus mutans* with its large sized zone of inhibition
3. Effect of 100 μL of Ag-NPs on *Streptococcus mutans* with its large zone of inhibition
4. Effect of Amoxicillin on *Streptococcus mutans* with its apparent zone of inhibition



Figure 4 - Showcasing the effect of various concentrations of Ag-NPs on *Staphylococcus aureus* with their zones of inhibition:

1. Effect of 25 μ L of Ag-NPs on *Staphylococcus aureus* with its moderately sized zone of inhibition
2. Effect of 50 μ L of Ag-NPs on *Staphylococcus aureus* with its apparent zone of inhibition
3. Effect of 100 μ L of Ag-NPs on *Staphylococcus aureus* with its large sized zone of inhibition

4. Effect of Amoxicillin on *Staphylococcus aureus* with its apparent zone of inhibition




Figure 5 - Showcasing the effect of various concentrations of Ag-NPs along with the positive control (Amoxicillin)on *Enterococcus faecalis* with their zones of inhibition:

1. Effect of 25 µL of Ag-NPs on *Enterococcus faecalis* with its moderately sized zone of inhibition
2. Effect of 50 µL of Ag-NPs on *Enterococcus faecalis* with its large sized zone of inhibition

3. Effect of 100 μL of Ag-NPs on *Enterococcus faecalis* with its large sized zone of inhibition
4. Effect of Amoxicillin on *Enterococcus faecalis* with its highly apparent zone of inhibition




Figure 6 – Antibacterial activity of *T. chebula* mediated silver nanoparticles

Bar graph with error bars showing the zones of inhibition for all three dilutions of Ag-NPs and the standard antibiotic (Amoxicillin) on the three different organisms. The three organisms - *Enterococcus faecalis*, *Streptococcus mutans* and *Staphylococcus aureus* are grouped in the 'X' axis and the measurements of the zones of inhibition in millimetre units are denoted on the 'Y'

axis. The blue bars depict the zones of inhibition for 25 µL units of the Ag-NPs , red depicts 50µL , green depicts 100 µL and yellow depicts the positive control Amoxicillin. For *S. aureus*, the zone of inhibition was significantly higher than Amoxicillin at all the tested concentrations of Ag-NPs ($p<0.05$), whereas for *E.faecalis*, it was significantly lower than amoxicillin ($p<0.05$). For *S. mutans* at 25 µL concentration the zone of inhibition was significantly lower than amoxicillin ($p<0.05$) whereas at higher concentrations there was no significant difference with amoxicillin ($p>0.05$)

Table 1 – Antibacterial activity of *T. chebula* mediated silver nanoparticles- Descriptive statistics

Table 1 depicts the descriptive statistics of the zone of inhibition of the various concentrations of the biosynthesised silver nanoparticle's antimicrobial activity along with the standard antibiotic on the three microbial species

| Descriptives | | | | | | | | | |
|----------------------------------|--------|----|-------|----------------|------------|----------------------------------|-------------|---------|---------|
| | | N | Mean | Std. Deviation | Std. Error | 95% Confidence Interval for Mean | | Minimum | Maximum |
| | | | | | | Lower Bound | Upper Bound | | |
| Absorbance of <i>S. mutans</i> | 25 µl | 3 | 18.67 | .577 | .333 | 17.23 | 20.10 | 18 | 19 |
| | 50 µl | 3 | 21.00 | .000 | .000 | 21.00 | 21.00 | 21 | 21 |
| | 100 µl | 3 | 21.33 | .577 | .333 | 19.90 | 22.77 | 21 | 22 |
| | AB | 3 | 20.33 | .577 | .333 | 18.90 | 21.77 | 20 | 21 |
| | Total | 12 | 20.33 | 1.155 | .333 | 19.60 | 21.07 | 18 | 22 |
| Absorbance of <i>S. aureus</i> | 25 µl | 3 | 17.67 | .577 | .333 | 16.23 | 19.10 | 17 | 18 |
| | 50 µl | 3 | 20.33 | .577 | .333 | 18.90 | 21.77 | 20 | 21 |
| | 100 µl | 3 | 25.67 | .577 | .333 | 24.23 | 27.10 | 25 | 26 |
| | AB | 3 | 16.00 | .000 | .000 | 16.00 | 16.00 | 16 | 16 |
| | Total | 12 | 19.92 | 3.848 | 1.111 | 17.47 | 22.36 | 16 | 26 |
| Absorbance of <i>E. faecalis</i> | 25 µl | 3 | 18.33 | .577 | .333 | 16.90 | 19.77 | 18 | 19 |
| | 50 µl | 3 | 25.67 | .577 | .333 | 24.23 | 27.10 | 25 | 26 |
| | 100 µl | 3 | 27.33 | .577 | .333 | 25.90 | 28.77 | 27 | 28 |
| | AB | 3 | 33.67 | .577 | .333 | 32.23 | 35.10 | 33 | 34 |
| | Total | 12 | 26.25 | 5.723 | 1.652 | 22.61 | 29.89 | 18 | 34 |

Table 2 – One way ANOVA

Table 2 depicts the one way ANOVA analysis performed for the various concentrations of the silver nanoparticle's antimicrobial activity on the three microbial species as observed in this study, where we have found statistically significant differences between the groups ($p < 0.05$).

| ANOVA | | | | | | |
|----------------------------------|----------------|----------------|----|-------------|---------|------|
| | | Sum of Squares | df | Mean Square | F | Sig. |
| Absorbance of <i>S. mutans</i> | Between Groups | 12.667 | 3 | 4.222 | 16.889 | .001 |
| | Within Groups | 2.000 | 8 | .250 | | |
| | Total | 14.667 | 11 | | | |
| Absorbance of <i>S. aureus</i> | Between Groups | 160.917 | 3 | 53.639 | 214.556 | .000 |
| | Within Groups | 2.000 | 8 | .250 | | |
| | Total | 162.917 | 11 | | | |
| Absorbance of <i>E. faecalis</i> | Between Groups | 357.583 | 3 | 119.194 | 357.583 | .000 |
| | Within Groups | 2.667 | 8 | .333 | | |
| | Total | 360.250 | 11 | | | |

Table 3 – Post Hoc (Tukey HSD) test results

Tabulation 3 showing pairwise comparison between groups using Post Hoc (Tukey HSD) test results, with the confidence interval set to 95%.

| Dependent Variable (Tukey HSD) | (I) Concentration | (J) Concentration | Mean Difference (I-J) | Std. Error | Sig. | 95% Confidence Interval | |
|-----------------------------------|----------------------|----------------------|-----------------------------|---------------|------|----------------------------|----------------|
| | | | | | | Lower Bound | Upper Bound |
| Absorbance of <i>S. mutans</i> | 25 µl | 50 µl | -2.333 [*] | .408 | .002 | -3.64 | -1.03 |
| | | 100 µl | -2.667 [*] | .408 | .001 | -3.97 | -1.36 |

| | | | | | | | |
|-------------------------------------|---------------|-------------|----------------------|------|------|--------|--------|
| Absorbance of S. aureus | | Amoxicillin | -1.667 [*] | .408 | .015 | -2.97 | -.36 |
| | 50 µl | 100 µl | -.333 | .408 | .845 | -1.64 | .97 |
| | | Amoxicillin | .667 | .408 | .414 | -.64 | 1.97 |
| | 100 µl | Amoxicillin | 1.000 | .408 | .144 | -.31 | 2.31 |
| | 25 µl | 50 µl | -2.667 [*] | .408 | .001 | -3.97 | -1.36 |
| | | 100 µl | -8.000 [*] | .408 | .000 | -9.31 | -6.69 |
| | | Amoxicillin | 1.667 [*] | .408 | .015 | .36 | 2.97 |
| | 50 µl | 100 µl | -5.333 [*] | .408 | .000 | -6.64 | -4.03 |
| | | Amoxicillin | 4.333 [*] | .408 | .000 | 3.03 | 5.64 |
| | 100 µl | Amoxicillin | 9.667 [*] | .408 | .000 | 8.36 | 10.97 |
| Absorbance of E. faecalis | 25 µl | 50 µl | -7.333 [*] | .471 | .000 | -8.84 | -5.82 |
| | | 100 µl | -9.000 [*] | .471 | .000 | -10.51 | -7.49 |
| | | Amoxicillin | -15.333 [*] | .471 | .000 | -16.84 | -13.82 |
| | 50 µl | 100 µl | -1.667 [*] | .471 | .031 | -3.18 | -.16 |
| | | Amoxicillin | -8.000 [*] | .471 | .000 | -9.51 | -6.49 |

| | | | | | | | |
|--|--------|-------------|---------|------|------|-------|-------|
| | 100 µl | Amoxicillin | -6.333* | .471 | .000 | -7.84 | -4.82 |
|--|--------|-------------|---------|------|------|-------|-------|

As deduced from Figures 3 and 6, 25 µL of the Ag-NP solution had the least efficacy against *Streptococcus mutans* with only a moderately sized zone of inhibition measuring up to 18.7 mm. 50 µL of the Ag-NP solution had a considerable efficacy against *Streptococcus mutans* with a large zone of inhibition of 21 mm. 100 µL of the Ag-NP solution had the best effect on *Streptococcus mutans* out of all the test samples, with a decently apparent zone of inhibition of 21.3 mm. The positive control used was Amoxicillin which had the second best action against *Streptococcus mutans* with its slightly smaller zone of inhibition of 20.3 mm.

Figures 4 and 6 demonstrate the efficacy of Ag-NPs on *Staphylococcus aureus*, where 25 µL of the Ag-NP solution had the second lowest antimicrobial potential with a moderately sized zone of inhibition measuring 17.7 mm. 50 µL of the Ag-NP solution had a good efficacy with a visibly apparent zone of 20.3 mm. 100 µL of the Ag-NP solution had the best effect, with 25.7 mm as the zone of inhibition. Amoxicillin had the smallest zone of inhibition among all the test samples measuring only 16.0 mm, suggesting that Ag-NPs is an excellent solution for controlling *Staphylococcus aureus*.

The antimicrobial activity of Ag-NPs synthesized using *Terminalia chebula* against *Enterococcus faecalis* was concluded in Figures 5 and 6 - 25 µL of the sample yielded a zone of inhibition of 18.3 mm, 50 µL stood at 25.7 mm with a large zone of inhibition and 100 µL had a similar but slightly larger zone of inhibition of 27.3 mm. Amoxicillin had the highest antimicrobial activity against *Enterococcus faecalis*, with a zone of inhibition measuring up to 33.7 mm. Out of all the three organisms, it would appear that our Ag-NPs are the least effective against the *Enterococcus* species, birthing the need for better solutions.

Tables 1 and 2 depict the one way ANOVA analysis performed for the various concentrations of the silver nanoparticle's antimicrobial activity on the three species as observed in this study, where we have obtained statistically significant results. ($p < 0.05$) Table 3 shows the values obtained following a Post Hoc test (Tukey HSD), where we have obtained statistically significant

differences between the antimicrobial activities of the plant extract and the control on the various organisms.

In a study conducted by Kesarla *et al.* in 2012 where they synthesized similar silver nanoparticles using *Terminalia chebula* in order to study its various properties, they concluded that the nanoparticles showed a good antimicrobial activity towards the gram positive bacteria, *Staphylococcus aureus* and that it was an industrially smart idea to exploit said efficacy (47). This is in accordance with our findings as depicted i. Another such study carried out by Nandagopal *et al.* in 2014 said that silver nanoparticles synthesised using the benefits of *Terminalia chebula* had excellent antimicrobial and anticancer potentials at all concentrations, especially against **Multi Drug Resistant (MDR)** bacteria such as *Staphylococcus aureus* (48). Ankegowda *et al.* in 2020 put forward that Ag-NPs mediated by *T. chebula* had a decent but not extremely sensitive antimicrobial potential against *Streptococcus mutans* (49), which is also at par with our findings. Carounanidy *et al.* in 2007 attempted to synthesise a herbal mouthwash using *T. chebula* reduced Ag-NPs. They concluded that using this formulation helped to increase the pH of the oral environment and notably reduced the microbial count of *Streptococcus mutans*, thus playing a crucial role in the destruction of cariogenic bacteria (50).

Recently, there has been an increase in the resistance of *Staphylococcus aureus* and *Streptococcus mutans* towards normal antimicrobial therapy, leading to the failure of treatment modalities and the recurrence of infections (51). Hence, the need to design unconventional antimicrobial remedies is vital. Due to the intricate mode of action of silver nanoparticles, it is strenuous for pathogens to build effective resistance against it (52). It is rapid, high providing and effective against these bacteria which have been known to cause even cardiovascular disorders when left unsupervised in the past. Also, silver nanoparticles when compared to most antimicrobial agents, are less noxious because they inhibit the growth of bacteria at a much lower concentration (53). Considering the large number of advantages, it is admissible to suggest that silver nanoparticles are environmentally benign and economically attractive choices for antimicrobial agents used against *Staphylococcus aureus* and *Streptococcus mutans*. But since our study is an in-vitro investigation in essence and as it is tested against only a few chosen bacteria of the oral cavity, further research is needed to validate and increase the generalisability of our findings.

4. Conclusion

Recent research has found that biogenic synthesis of silver nanoparticles using fruit extract has various advantages, and that these materials have considerable potential for a variety of health-related applications. The nanoparticles have cappings made of plant extract that provide stability. This capping may have biological activity depending on the fruit extract employed, working in tandem with the nanoparticle core's action. These nanoparticles have a lot of potential in terms of controlling pathogenic oral germs. As a result, silver nanoparticles may be utilised to replace traditional antibacterial therapy.

References

1. Ma J, Wong H, Kong LB, Peng KW. Biomimetic processing of nanocrystallite bioactive apatite coating on titanium. *Nanotechnology*. 2003 Apr 15;14(6):619.
2. Zaman M, Ahmad E, Qadeer A, Rabbani G, Khan RH. Nanoparticles in relation to peptide and protein aggregation. *International journal of nanomedicine*. 2014;9:899.
3. Lansdown AB. Silver in health care: antimicrobial effects and safety in use. *Biofunctional textiles and the skin*. 2006;33:17-34.
4. Bruchez M, Moronne M, Gin P, Weiss S, Alivisatos AP. Semiconductor nanocrystals as fluorescent biological labels. *science*. 1998 Sep 25;281(5385):2013-6.
5. Zhang XF, Zhi-Guo liu, Wei shen, Sangiliyandi Gurunathan. SilverNanoparticles: Synthesis, Characterization, Properties, Applications, and Therapeutic Approaches. *International Journal of Molecular Sciences*. 2016;17:1534.
6. Wakshlak RB, Pedahzur R, Avnir D. Antibacterial activity of silver-killed bacteria: the "zombies" effect. *Scientific reports*. 2015 Apr 23;5(1):1-5.
7. Aneesa NN, Anitha R, Varghese S. Antidiabetic activity of ajwain oil in different in vitro models. *Journal of pharmacy & bioallied sciences*. 2019 Apr;11(2):142.
8. Jangid KR, Jayakumar ND, Varghese SS. Achievable therapeutic effects of *Myristica*

fragrans (Nutmeg) on periodontitis a short review. *International Journal of Pharmacy and Pharmaceutical Sciences*. 2014;6(5):591-4.

9. Ramesh A, Varghese SS, Doraiswamy J, Malaiappan S. Role of sulfiredoxin in systemic diseases influenced by oxidative stress. *Redox biology*. 2014 Jan 1;2:1023-8.
10. Gurunathan S, Kalishwaralal K, Vaidyanathan R, Venkataraman D, Pandian SR, Muniyandi J, Hariharan N, Eom SH. Biosynthesis, purification and characterization of silver nanoparticles using *Escherichia coli*. *Colloids and Surfaces B: Biointerfaces*. 2009 Nov 1;74(1):328-35.
11. Siddiqi KS, Rashid M, Rahman A, Husen A, Rehman S. Biogenic fabrication and characterization of silver nanoparticles using aqueous-ethanolic extract of lichen (*Usnea longissima*) and their antimicrobial activity. *Biomaterials research*. 2018 Dec;22(1):1-9.
12. Chowdhury NR, MacGregor-Ramiasa M, Zilm P, Majewski P, Vasilev K. 'Chocolate' silver nanoparticles: Synthesis, antibacterial activity and cytotoxicity. *Journal of colloid and interface science*. 2016 Nov 15;482:151-8.
13. Khan MS, Ahmad I, Chattopadhyay D, editors. *New Look to Phytomedicine: Advancements in Herbal Products as Novel Drug Leads*. Academic Press; 2018 Oct 23.
14. Khasim SM, Long C, Thammasiri K, Lutken H, editors. *Medicinal Plants: Biodiversity, Sustainable Utilization and Conservation*. Springer Nature; 2020 Apr 3.
15. Prabakar J, John J, Arumugham IM, Kumar RP, Sakthi DS. Comparing the effectiveness of probiotic, green tea, and chlorhexidine- and fluoride-containing dentifrices on oral microbial flora: A double-blind, randomized clinical trial. *Contemporary clinical dentistry*. 2018 Oct;9(4):560.
16. Mathew MG, Samuel SR, Soni AJ, Roopa KB. Evaluation of adhesion of *Streptococcus mutans*, plaque accumulation on zirconia and stainless steel crowns, and surrounding gingival inflammation in primary molars: Randomized controlled trial. *Clinical oral investigations*. 2020 Sep;24(9):3275-80.
17. Nam YJ, Hwang YS. Antibacterial and antioxidant effect of ethanol extracts of *Terminalia chebula* on *Streptococcus mutans*. *Clinical and Experimental Dental Research*. 2021 Jun 28.
18. Zayed SM, Aboulwafa MM, Hashem AM, Saleh SE. Biofilm formation by *Streptococcus mutans* and its inhibition by green tea extracts. *AMB Express*. 2021 Dec;11(1):1-0.
19. Garcia BA, Acosta NC, Tomar SL, Roesch LF, Lemos JA, Mugayar LR, Abranches J. Association of *Candida albicans* and Cbp+ *Streptococcus mutans* with early childhood caries recurrence. *Scientific reports*. 2021 May 24;11(1):1-1.
20. Blancas B, Lanzagorta MD, Jiménez-García LF, Lara R, Molinari JL, Fernández AM. Study of the ultrastructure of *Enterococcus faecalis* and *Streptococcus mutans* incubated with salivary antimicrobial peptides. *Clinical and Experimental Dental Research*. 2021 May 5.

21. Selvan SR, Ganapathy D. Efficacy of fifth generation cephalosporins against methicillin-resistant *Staphylococcus aureus*-A review. *Research Journal of Pharmacy and Technology*. 2016;9(10):1815-8.
22. Shaffer JR, Leslie EJ, Feingold E, Govil M, McNeil DW, Crout RJ, Weyant RJ, Marazita ML. Caries experience differs between females and males across age groups in Northern Appalachia. *International journal of dentistry*. 2015 May 27;2015.
23. Zhang S, Liu J, Lo EC, Chu CH. Dental caries status of Bulang preschool children in Southwest China. *BMC Oral Health*. 2014 Dec;14(1):1-7.
24. Ramesh A, Varghese S, Jayakumar ND, Malaiappan S. Comparative estimation of sulfiredoxin levels between chronic periodontitis and healthy patients–A case-control study. *Journal of periodontology*. 2018 Oct;89(10):1241-8.
25. Paramasivam A, Priyadharsini JV, Raghunandhakumar S, Elumalai P. A novel COVID-19 and its effects on cardiovascular disease. *Hypertension Research*. 2020 Jul;43(7):729-30.
26. Gokila S, Gomathi T, Vijayalakshmi K, Sukumaran A, Sudha PN. Development of 3D scaffolds using nanochitosan/silk-fibroin/hyaluronic acid biomaterials for tissue engineering applications. *International journal of biological macromolecules*. 2018 Dec 1;120:876-85.
27. Del Fabbro M, Karanxha L, Panda S, Bucci C, Doraiswamy JN, Sankari M, Ramamoorthi S, Varghese S, Taschieri S. Autologous platelet concentrates for treating periodontal infrabony defects. *Cochrane database of systematic reviews*. 2018(11).
28. Paramasivam A, Priyadharsini JV. MitomiRs: new emerging microRNAs in mitochondrial dysfunction and cardiovascular disease. *Hypertension Research*. 2020 Aug;43(8):851-3.
29. Jayaseelan VP, Arumugam P. Dissecting the theranostic potential of exosomes in autoimmune disorders. *Cellular & molecular immunology*. 2019 Dec;16(12):935-6.
30. Vellappally S, Al Kheraif AA, Divakar DD, Basavarajappa S, Anil S, Fouad H. Tooth implant prosthesis using ultra low power and low cost crystalline carbon bio-tooth sensor with hybridized data acquisition algorithm. *Computer Communications*. 2019 Dec 15;148:176-84.
31. Vellappally S, Al Kheraif AA, Anil S, Assery MK, Kumar KA, Divakar DD. Analyzing relationship between patient and doctor in public dental health using particle Memetic multivariable logistic regression analysis approach (MLRA2). *Journal of medical systems*. 2018 Oct;42(10):1-7.
32. Varghese SS, Ramesh A, Veeraiyan DN. Blended Module-Based Teaching in Biostatistics and Research Methodology: A Retrospective Study with Postgraduate Dental Students. *Journal of dental education*. 2019 Apr;83(4):445-50.
33. Venkatesan J, Singh SK, Anil S, Kim SK, Shim MS. Preparation, characterization and biological applications of biosynthesized silver nanoparticles with chitosan-fucoidan

coating. *Molecules*. 2018 Jun;23(6):1429.

34. Alsubait SA, Al Ajlan R, Mitwalli H, Aburaisi N, Mahmood A, Muthurangan M, Almadhri R, Alfayez M, Anil S. Cytotoxicity of different concentrations of three root canal sealers on human mesenchymal stem cells. *Biomolecules*. 2018 Sep;8(3):68.
35. Venkatesan J, Rekha PD, Anil S, Bhatnagar I, Sudha PN, Dechsakulwatana C, Kim SK, Shim MS. Hydroxyapatite from cuttlefish bone: isolation, characterizations, and applications. *Biotechnology and Bioprocess Engineering*. 2018 Aug;23(4):383-93.
36. Vellappally S, Al Kheraif AA, Anil S, Wahba AA. IoT medical tooth mounted sensor for monitoring teeth and food level using bacterial optimization along with adaptive deep learning neural network. *Measurement*. 2019 Mar 1;135:672-7.
37. PradeepKumar AR, Shemesh H, Nivedhitha MS, Hashir MM, Arockiam S, Maheswari TN, Natanasabapathy V. Diagnosis of Vertical Root Fractures by Cone Beam Computed Tomography in Root Filled Teeth with Confirmation by Direct Visualization-A Systematic Review and Meta-Analysis. *Journal of Endodontics*. 2021 May 11.
38. Ramani P, Tilakaratne WM, Sukumaran G, Ramasubramanian A, Krishnan RP. Critical appraisal of different triggering pathways for the pathobiology of pemphigus vulgaris-A review. *Oral Diseases*. 2021 Jun 21.
39. Ezhilarasan D, Lakshmi T, Subha M, Deepak Nallasamy V, Raghunandhakumar S. The ambiguous role of sirtuins in head and neck squamous cell carcinoma. *Oral Diseases*. 2021 Mar 1.
40. Sarode SC, Gondivkar S, Sarode GS, Gadbail A, Yuwanati M. Hybrid oral potentially malignant disorder: A neglected fact in oral submucous fibrosis. *Oral oncology*. 2021 Jun 17:105390.
41. Kavarthapu A, Gurumoorthy K. Linking chronic periodontitis and oral cancer: A review. *Oral Oncology*. 2021 Jun 16:105375.
42. Babushkina EA, Belokopytova LV, Grachev AM, Meko DM, Vaganov EA. Variation of the hydrological regime of Bele-Shira closed basin in Southern Siberia and its reflection in the radial growth of *Larix sibirica*. *Regional Environmental Change*. 2017 Aug;17(6):1725-37.
43. Aldhuwayhi S, Mallineni SK, Sakhamuri S, Thakare AA, Mallineni S, Sajja R, Sethi M, Nettam V, Mohammad AM. Covid-19 knowledge and perceptions among dental specialists: a cross-sectional online questionnaire survey. *Risk Management and Healthcare Policy*. 2021;14:2851.
44. VIDHYA S, ROSE AL, PRIYA FJ, KEERTHANA T, PRIYADHARSHINI R. Anti-urolithiatic Activity of Silver Nanoparticles of *Terminalia chebula* Bark.
45. Espenti CS, Rao KK, Rao KM. Bio-synthesis and characterization of silver nanoparticles using *Terminalia chebula* leaf extract and evaluation of its antimicrobial potential. *Materials*

letters. 2016 Jul 1;174:129-33.

46. Ramesh PS, Kokila T, Geetha D. Plant mediated green synthesis and antibacterial activity of silver nanoparticles using *Embllica officinalis* fruit extract. *Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy*. 2015 May 5;142:339-43.
47. Kumar KM, Sinha M, Mandal BK, Ghosh AR, Kumar KS, Reddy PS. Green synthesis of silver nanoparticles using *Terminalia chebula* extract at room temperature and their antimicrobial studies. *Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy*. 2012 Jun 1;91:228-33.
48. Nandagopal S, Kumar AG, Dhanalaksmi DP, Prakash P. Bioprospecting the antibacterial and anticancer activities of silver nanoparticles synthesized using *Terminalia chebula* seed extract. *Int. J. Pharm. Pharm. Sci*. 2014;6:36837.
49. Ankegowda VM, Kollur SP, Prasad SK, Pradeep S, Dhramashekara C, Jain AS, Prasad A, Srinivasa C, Sridhara Setty PB, Gopinath SM, Bahkali AH. Phyto-mediated synthesis of silver nanoparticles using *Terminalia chebula* fruit extract and evaluation of its cytotoxic and antimicrobial potential. *Molecules*. 2020 Jan;25(21):5042.
50. Carounanidy U, Satyanarayanan R, Velmurugan A. Use of an aqueous extract of *Terminalia chebula* as an anticaries agent: a clinical study. *Indian Journal of Dental Research*. 2007 Oct 1;18(4):152.
51. Hu P, Lv B, Yang K, Lu Z, Ma J. Discovery of myricetin as an inhibitor against *Streptococcus mutans* and an anti-adhesion approach to biofilm formation. *International Journal of Medical Microbiology*. 2021 May 1;311(4):151512.
52. Ajdary M, Eghbali S, Mahabadi VP, Keyhanfar F, Varma RS. Toxicity of silver nanoparticles on endometrial receptivity in female mice. *Canadian journal of physiology and pharmacology*. 2021;99(12):1264-71.
53. Bruna T, Maldonado-Bravo F, Jara P, Caro N. Silver nanoparticles and their antibacterial applications. *International Journal of Molecular Sciences*. 2021 Jan;22(13):7202.